WHOLE LIVER RADIATION DOSE ESCALATION TRIAL UTILIZING ETHYOL AMIFOSTINE

使用乙基氨磷汀的全肝辐射剂量递增试验

• 批准号: 6303452
• 负责人: CORNELIUS J MCGINN
• 金额: $ 0.02万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2001-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6303452
• 关键词: clinical research; clinical trial phase I; combination cancer therapy; human subject; liver neoplasms; neoplasm /cancer chemotherapy; neoplasm /cancer radiation therapy; radiation therapy dosage; thiophosphate; whole body irradiation dosage

Although radiation has proven efficacy in the treatment of patients with cancers that started in or spread to the liver, its usefulness in the treatment of the whole liver is limited by the low total dose that can be safely tolerated. In this phase 1 study, Ethyol (amifostine) will be used in attempt to allow delivery of a higher total dose to the whole liver. This agent has been developed to selectively protect normal tissues against the toxicities of chemotherapy and radiation.

虽然放射已被证明在治疗开始于或扩散到肝脏的癌症患者中有效，但其在治疗整个肝脏中的有用性受到可以安全耐受的低总剂量的限制。 在这项I期研究中，将使用Ethyol（氨磷汀），试图向整个肝脏输送更高的总剂量。 这种药物被开发用于选择性地保护正常组织免受化疗和放疗的毒性。